BPDCN: Epidemiology, Pathophysiology, and Diagnosis
BPDCN: Epidemiology, Pathophysiology, and Diagnosis
Sep 27, 2022
targetedonc.com
The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KRAS G12C-NSCLC, Adding Nivolumab to Tivozanib Yields No benefit in RCC, and More
The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KR…
8 months ago
targetedonc.com
Belumosudil Shows Sustained Efficacy and Safety for Chronic GVHD
Belumosudil Shows Sustained Efficacy and Safety for Chronic G…
Mar 11, 2024
targetedonc.com
Nirogacestat Shows Statistically Significant Improvements in Desmoid Tumors
Nirogacestat Shows Statistically Significant Improvements in Desm…
Nov 28, 2023
targetedonc.com
Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Cancer
Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Can…
11 months ago
targetedonc.com
Safety Challenges of Oncolytic Virus Therapy
Safety Challenges of Oncolytic Virus Therapy
Jun 12, 2024
targetedonc.com
The Role of Menin Inhibitors in AML
The Role of Menin Inhibitors in AML
Nov 1, 2022
targetedonc.com
An Introduction to Front-line Nivolumab/Ipilimumab Therapy fo…
5 months ago
targetedonc.com
Advantages of SC HER2 Therapy Over IV Administration in Breast C…
Mar 7, 2024
targetedonc.com
An Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Can…
Nov 30, 2023
targetedonc.com
Strategic JAK Inhibitor Sequencing: Translating SIMPLIFY I/II Outcome…
1 month ago
targetedonc.com
Evolving Treatment Landscape in Metastatic Castration-Resistant Pr…
5 days ago
targetedonc.com
Myeloma Community Responds Positively to Expanding Role of M…
3 weeks ago
targetedonc.com
BrECADD Shows Promise as New Standard for Advanced Hodgkin L…
Jun 1, 2024
targetedonc.com
INAVO120: Inavolisib Combination Therapy in PIK3CA-Mutated Breas…
1 year ago
targetedonc.com
Phase 3 NATALEE Study Assesses Ribociclib Plus ET in Early Breast …
Jul 1, 2023
targetedonc.com
Unmet Needs Persist for Patients with Melanoma
11 months ago
targetedonc.com
Program Development and SOPs for Bispecific Engagers
Dec 14, 2023
targetedonc.com
T-DXd Shows Promise in Treating HER2 Breast Cancer With Brain M…
8 months ago
targetedonc.com
Newly Diagnosed mHSPC: First-Line Treatment Options
5 months ago
targetedonc.com
Key Takeaways from SABCS 2023
Jan 8, 2024
targetedonc.com
ESMO 2024: Updates in NIAGARA Study
8 months ago
targetedonc.com
Exploring Updates on AMPLIFY at ASH 2024
5 months ago
targetedonc.com
Advancements in AML Treatment in the Past 10 Years
9 months ago
targetedonc.com
Reviewing the Options for Bladder Cancer in Different Settings
5 months ago
targetedonc.com
SC Pembrolizumab in NSCLC May Boost Patient Experience, Efficiency
1 month ago
targetedonc.com
BTK Inhibition and the Mechanism of Action of Ibrutinib
Aug 20, 2013
targetedonc.com
Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripal…
3 months ago
targetedonc.com
First-Line Therapy Options in Diffuse Large B-Cell Lymphoma
Jul 23, 2021
targetedonc.com
Trastuzumab Deruxtecan Shows Clinical Activity in HER2 Solid Tu…
Aug 7, 2023
targetedonc.com
See more videos
Static thumbnail place holder